Azienda Unita Sanitaria Locale Di Piacenza — Clinical Trial Site

69 Registered trials

33 Currently recruiting

Organisation

Azienda Unita Sanitaria Locale Di Piacenza

Location

Piacenza, Italy

Identifier

ORG-100011206

Address

Via Giuseppe Taverna 49, 29121, Italy

Departments

Cardiologia e UTIC
Cardiology
DIPARTIMENTO DI ONCO-EMATOLOGIA
Dipartimento di Oncoematologia, UOC oncologia medica
DIPARTIMENTO ONCOLOGIA - EMATOLOGIA
DIPARTIMENTO ONCOLOGIA - EMATOLOGIA - UO EMATOLOGIA CENTO TRAPIANTI MIDOLLO OSSEO
Dipartimento Oncologia-Ematologia - UO EMATOLOGIA E CENTRO TRAPIANTI MIDOLLO
Divisione di Oncologia
Ematologia
General Surgery
Hematology
Medical oncology
N/A
NA
Nephrology
Nephrology and Dialysis
Oncoematologia
Oncoematology
Oncohematology
Oncologia ed Ematologia
Oncologia Medica
Oncologia Medica ed Ematologia - Ospedale Guglielmo da Saliceto -Piacenza
Oncologia Medica ed Ematologia -Osp. Guglielmo da Saliceto
Oncologia-ematologia
Oncology
Oncology and Hematology
Oncology Department
Onomatology
Ospedale Guglielmo da Saliceto, Dipartimento di Oncoematologia, UOC oncologia medica
OU Nephrology and Dialysis
Pediatrics and Neonatology Units
Terapia del Dolore
U.O. Ematologia
U.O. Ematologia - Ospedale Guglielmo da Saliceto
U.O. Oncologia Medica
U.O. Oncologia Medica Via Giuseppe Taverna 49, Piacenza, 29121
U.O.Ematologia
UO Ematologia e CTMO
UO Oncologia Medica
UOC Ematologia e Centro Trapianti
UOC Nefrologia e Dialisi
UOC Nefrologia-Dialisi
UOC Pediatria e Neonatologia

Clinical trials at this site (69)

Search interface

A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastat… Pending

2024-519519-32-00 urothelial cancer 4
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiot… Pending

2024-520081-65-00 NSCLC non-small cell lung cancer 4
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending

2025-521583-35-00 non-small cell lung cancer (NSCLC) 4
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending

2025-522084-15-00 metastatic NSCLC patients 10
A clinical study of enlicitide in children with high cholesterol (MK-0616-029) Recruiting

2024-519068-42-00 Heterozygous Familial Hypercholesterolemia in pediatr 10 2026-02-12
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Acute myeloid leukemia 5 2025-02-27
Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade… Recruiting

2024-513317-12-00 Pancreatic cancer 5 2025-02-05
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting

2024-516874-31-00 Patients with a low-grade serous epithelial carcinoma o 5 2024-12-10
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Advanced or metastatic untreated EGFR mutation positive 4 2020-03-10
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li… Recruiting

2025-521666-10-01 Mantle Cell Lymphoma 4 2026-06-08
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting

2025-520825-19-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 5 2025-12-16
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting

2024-512696-12-00 BCR-ABL1+ Chronic Myeloid Leukemia 4 2025-06-24
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non… Recruiting

2023-506206-38-00 Diffuse Large B-cells non-Hodgkin Lymphoma 4 2025-04-09
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01